RXRX Earnings Date: Nov 2, 2026 (Estimated) — Recursion Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is RXRX's next earnings date?
Recursion Pharmaceuticals, Inc. (RXRX) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.22 on revenue of $14.8M.
How did RXRX do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Recursion Pharmaceuticals, Inc. posted EPS of -$0.25 versus the -$0.24 estimate, a miss of 4.2%. Revenue was $7.7M against a $11.0M estimate. The stock's 1-day post-earnings move was -4.2%.
How much does RXRX stock move after earnings?
RXRX beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.2% (up or down) in the day after earnings.
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.24 | -0.25 | -4.17% | $7.7M | ❌ Miss | -4.23% | +1.21% | +2.11% |
| 2026-05-06 | Q1 2026 | -0.27 | -0.22 | +18.52% | $6.5M | ✅ Beat | +1.78% | -6.53% | +12.76% |
| 2026-02-25 | Q4 2025 | -0.30 | -0.21 | +30.00% | $35.5M | ✅ Beat | +6.80% | +0.28% | -10.20% |
| 2025-11-05 | Q3 2025 | -0.38 | -0.36 | +5.26% | $5.2M | ✅ Beat | -0.80% | -5.80% | -1.60% |
| 2025-08-05 | Q2 2025 | -0.35 | -0.41 | -17.14% | $19.2M | ❌ Miss | -4.66% | -8.79% | -20.17% |
| 2025-02-28 | Q4 2024 | -0.42 | -0.53 | -26.19% | $4.5M | ❌ Miss | -2.09% | -18.64% | -24.25% |
| 2024-02-27 | Q4 2023 | -0.45 | -0.42 | +6.67% | $10.9M | ✅ Beat | -16.62% | -23.26% | -34.47% |
| 2023-08-08 | Q2 2023 | -0.37 | -0.38 | -2.70% | $11.0M | ❌ Miss | +4.71% | -15.50% | -17.95% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $7.7M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| License and Service | 95.2% | $7.3M | -61.8% | $18.9M | $14.8M | $19.1M | $5.0M |
| Grant | 4.8% | $367K | +205.8% | $48K | — | $120K | $192K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.